98%
921
2 minutes
20
The prevalence of myopia is increasing extensively worldwide. The number of people with myopia in 2020 is predicted to be 2.6 billion globally, which is expected to rise up to 4.9 billion by 2050, unless preventive actions and interventions are taken. The number of individuals with high myopia is also increasing substantially and pathological myopia is predicted to become the most common cause of irreversible vision impairment and blindness worldwide and also in Europe. These prevalence estimates indicate the importance of reducing the burden of myopia by means of myopia control interventions to prevent myopia onset and to slow down myopia progression. Due to the urgency of the situation, the European Society of Ophthalmology decided to publish this update of the current information and guidance on management of myopia. The pathogenesis and genetics of myopia are also summarized and epidemiology, risk factors, preventive and treatment options are discussed in details.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369912 | PMC |
http://dx.doi.org/10.1177/1120672121998960 | DOI Listing |
Clin Ophthalmol
September 2025
Faculty of Biomedical Engineering, Czech Technical University in Prague, Kladno, Czech Republic.
Aim: The objective of this study was to evaluate the efficacy of DIMS (Defocus Incorporated Multiple Segments) in comparison to control group (CTRL) in a wide age group of European progressive myopes (6-26 years).
Methods: In this prospective, non-randomised observational study, 78 myopes with progression myopia to -0.25 to -8.
Cureus
August 2025
Ophthalmology, Cornea and Refractive Surgery, John A. Moran Eye Center, University of Utah School of Medicine, Salt Lake City, USA.
Purpose This study aims to compare the initial three-month outcomes of a single-center experience with small incision lenticule extraction (SMILE) for correction of myopia and myopic astigmatism using the VisuMax 500 (Carl Zeiss Meditec, Jena, Germany) versus the VisuMax 800 (SMILE Pro®; Carl Zeiss Meditec, Jena, Germany). This experience is compared to the US Food and Drug Administration approval studies and published literature. Patients and methods The initial 45 eyes (23 patients) that underwent SMILE with the VisuMax 500 in 2018 were compared with the initial 42 eyes (21 patients) that underwent SMILE Pro® with the VisuMax 800 in 2024.
View Article and Find Full Text PDFFASEB J
September 2025
Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Age-related cataract (ARC) represents a major global cause of visual impairment, with ultraviolet B (UVB) radiation recognized as a primary contributor to oxidative damage in the lens. FOXO3, a key regulator of aging, apoptosis, and oxidative stress-induced cell death, was investigated for its role and regulatory mechanisms in UVB-induced oxidative stress using human lens epithelial cells (HLECs). A progressive decrease in FOXO3 protein expression was observed in the lens capsules across various stages of cataract progression, as well as in UVB-exposed animal models and UVB-treated HLECs.
View Article and Find Full Text PDFInvest Ophthalmol Vis Sci
September 2025
Department of Ophthalmology, Edward S. Harkness Eye Institute, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, Columbia University, New York, New York, United States.
Purpose: To characterize a no b-wave (nob) mouse model of congenital stationary night blindness (CSNB) caused by a Grm6 variant that disrupts photoreceptor-to-bipolar cell signaling. Additionally, we aim to evaluate the efficacy of gene therapy in restoring visual function.
Methods: The nob mouse was generated through selective breeding to regenerate the nob phenotype.
Invest Ophthalmol Vis Sci
September 2025
Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore.
Purpose: The purpose of this study was to investigate the focal relationship between choroidal thickness and retinal sensitivity in myopic eyes.
Methods: Participants underwent swept-source optical coherence tomography (SS-OCT) imaging and microperimetry testing. Choroidal thicknesses were obtained by segmenting the SS-OCT scans using a deep-learning approach.